Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1501 to 1515 of 1809 results for nice guidelines

  1. Familial breast cancer (CG14)

    This guidance has been updated and replaced by NICE guideline CG41.

  2. Transurethral radiofrequency needle ablation of the prostate (IPG15)

    This guidance has been updated and replaced by NICE guideline CG97.

  3. Community engagement (PH9)

    This guidance has been updated and replaced by NICE guideline NG44.

  4. Substance misuse interventions for vulnerable under 25s (PH4)

    This guidance has been updated and replaced by NICE guideline NG64.

  5. Sexually transmitted infections and under-18 conceptions: prevention (PH3)

    This guidance has been updated and replaced by NICE guideline NG221.

  6. HIV testing: increasing uptake in black Africans (PH33)

    This guidance has been updated and replaced by NICE guideline NG60.

  7. Looked-after children and young people (PH28)

    This guidance has been updated and replaced by NICE guideline NG205.

  8. The clinical effectiveness and cost effectiveness of new drugs for bipolar disorder (TA66)

    This guidance has been updated and replaced NICE guideline CG38.

  9. The clinical effectiveness and cost effectiveness of bupropion (Zyban) and Nicotine Replacement Therapy for smoking cessation (TA39)

    This guidance has been updated and replaced by NICE guideline PH10

  10. Guidance on the use of vinorelbine for the treatment of advanced breast cancer (TA54)

    This guidance has been updated and replaced by NICE guideline CG81.

  11. The clinical effectiveness and cost effectiveness of surgery for people with morbid obesity (TA46)

    This guidance has been updated and replaced by NICE guideline CG43.

  12. The clinical effectiveness and cost effectiveness of newer atypical antipsychotic drugs for schizophrenia (TA43)

    This guidance has been updated and replaced by NICE guideline CG82.

  13. Denosumab for the treatment of therapy-induced bone loss in non-metastatic prostate cancer (terminated appraisal) (TA194)

    This guidance has been updated and replaced by NICE guideline CG175.

  14. Guidance on the use of patient-education models for diabetes (TA60)

    This guidance has been replaced by NICE guideline NG17.

  15. Guidance on the use of long‑acting insulin analogues for the treatment of diabetes – insulin glargine (TA53)

    This guidance has been replaced by NICE guideline NG17.